Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06116253 · ClinicalTrials.gov registry record · NA
Advanced Diffusion Imaging in Renal Cancer Patients
A NA study of Renal Cancer, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT06116253: Recruiting NA study of Renal Cancer, sponsored by NYU Langone Health.
NCT06116253 is a NA study of Renal Cancer that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 90 participants, below the 607-participant average among 29 other Renal Cancer trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06116253, a NA study of Renal Cancer, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to apply advanced diffusion imaging in a two-pronged assessment of renal mass patients: (1) characterization of lesion malignancy and subtype, and (2) prediction of renal function stability or decline following partial nephrectomy.
Primary Outcome
Intravoxel incoherent imaging-MRI (IVIM-MRI) data will be used to predict lesion type.
Conditions Studied
Interventions
- DEVICE Magnetic Resonance Imaging (MRI) Scan
- DRUG Tc-99m Pentetate
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2022-12-01 |
| Est. Completion | 2028-12-01 |
| Phase | NA |
What NCT06116253 shows while recruiting
NCT06116253 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 607-participant average among 29 other Renal Cancer trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Renal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Magnetic Resonance Imaging (MRI) Scan is the first listed.
NCT06116253 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06116253 about?
NCT06116253 is a clinical study titled "Advanced Diffusion Imaging in Renal Cancer Patients". The objective of this study is to apply advanced diffusion imaging in a two-pronged assessment of renal mass patients: (1) characterization of lesion malignancy and subtype, and (2) prediction of renal function stability or decline following partial nephrectomy.
What is the current status of trial NCT06116253?
This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2022-12-01. Estimated completion is 2028-12-01.
What conditions does trial NCT06116253 study?
This clinical trial studies the following conditions: Renal Cancer.
What interventions are being tested in trial NCT06116253?
The interventions under investigation include: Magnetic Resonance Imaging (MRI) Scan (DEVICE), Tc-99m Pentetate (DRUG).
Who is sponsoring clinical trial NCT06116253?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06116253 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06116253's enrollment target sits among peer trials
90 19th of 29 higher than 11 of 29 other Renal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Video Education With Result Dependent dIsclosure
RECRUITING · NA
-
Decision Aid (DA) for Renal Patients
RECRUITING · NA
-
Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
ACTIVE NOT RECRUITING · NA
-
The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)
ACTIVE NOT RECRUITING · NA
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI